didanosine and Atrophy

didanosine has been researched along with Atrophy* in 3 studies

Trials

1 trial(s) available for didanosine and Atrophy

ArticleYear
Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.
    American journal of ophthalmology, 1992, Jan-15, Volume: 113, Issue:1

    To assess the safety and antiretroviral activity of 2',3'-dideoxyinosine, we enrolled 43 children with symptomatic (Centers for Disease Control class P-2) human immunodeficiency virus infection in a Phase I-II study and monitored them prospectively for the development of ocular complications secondary to HIV infection or drug toxicity. Follow-up ranged from 12 to 103 weeks with a median follow-up of 71 weeks. Three of 43 children (7.0%) developed peripheral atrophy of the retinal pigment epithelium during treatment with 2',3'-dideoxyinosine. The two children with the most severe retinal atrophy were enrolled in the study at the highest dosage studied (540 mg/m2/day). In contrast to findings in children, no retinal atrophy in HIV-infected adults treated with 2',3'-dideoxyinosine has been evident to date.

    Topics: Atrophy; Child; Child, Preschool; Didanosine; Drug Evaluation; Electrooculography; Electroretinography; Female; Follow-Up Studies; Fundus Oculi; HIV Infections; HIV-1; Humans; Male; Pigment Epithelium of Eye; Prospective Studies; Retina; Retinal Diseases; Zidovudine

1992

Other Studies

2 other study(ies) available for didanosine and Atrophy

ArticleYear
A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.
    Medicina (Kaunas, Lithuania), 2022, May-30, Volume: 58, Issue:6

    Topics: Adult; Atrophy; Choroid Diseases; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Hydroxychloroquine; Retinal Degeneration; Tenofovir; Tomography, Optical Coherence

2022
Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
    Biological research for nursing, 2011, Volume: 13, Issue:1

    To describe lipoatrophy of the plantar pedis fat pads in human immunodeficiency virus (HIV) patients with or without long-term antiretroviral therapy (ART); to compare the characteristics of ART patients with and without plantar pedis lipoatrophy; and to examine the effects of HIV and metabolic/cardiovascular risk parameters and treatment history on plantar pedis lipoatrophy.. Participants included 134 patients who started protease inhibitors in antiretroviral therapy (ART) in 1996 and 49 treatment-naive patients, recruited in 2004. Participants were examined and graded for lipoatrophy of five body compartments including the plantar fat pads. Baseline HIV- and ART-related factors were documented together with follow-up metabolic/ cardiovascular risk parameters.. Plantar pedis lipoatrophy occurred more often among ART patients (60%) than among treatment-naive patients (12%; p < .001). ART patients with plantar lipoatrophy were older, had higher plasminogen activator inhibitor 1 (PAI-1) values, a higher prevalence of lipoatrophy in other body compartments, and longer stavudine and didanosine treatment history as compared to patients without plantar lipoatrophy. Multiple logistic regression modeling revealed that among the metabolic/cardiovascular parameters, increased PAI-1 was strongly and positively associated with plantar lipoatrophy. Among the treatment history parameters, didanosine was the strongest independent predictor for plantar lipoatrophy. Increased PAI-1 was not associated to lipoatrophy in any other location.. Plantar lipoatrophy is common among patients on long-term ART and, though often overlooked, may cause significant discomfort. The association to PAI-1, a well-known marker of increased cardiovascular risk, is intriguing and places further focus on the need for an active approach to evaluating and lowering cardiovascular risk factors in long-term HIV treatment.

    Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atrophy; Cardiovascular Diseases; Cross-Sectional Studies; Didanosine; Foot; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prevalence; Risk Factors; Stavudine

2011